Startpagina / Markten

Markten

Op deze pagina staan de eisen voor de levering van peptides in 35 markten in Europa.

De marktpagina's

Elke markt heeft een eigen pagina. Die noemt de bevoegde toezichthouder, het gepubliceerde standpunt en elke bron met datum en link naar de uitgevende instantie. Zo is elke uitspraak bij de bron te controleren.

35 markten, 141 gedateerde bronnen, stand 20-08-2026.

Standpunt per stof en per markt

Daarnaast is er een tabel met het standpunt per stof en per markt. Die laat zien wat elke toezichthouder over elke stof heeft gepubliceerd, met in elke cel de bron.

Hoe wij dit naslagwerk gebruiken

Dit is het naslagwerk dat wij zelf raadplegen wanneer een koper vraagt of een stof naar zijn eigen markt geleverd kan worden. Het staat gepubliceerd, zodat het antwoord er al is voordat u het vraagt.

Engelstalige marktpagina's

De 35 afzonderlijke marktpagina's zijn voorlopig in het Engels gepubliceerd.

Juridische kennisgeving

Dit is geen juridisch advies. De volledige leveringsvoorwaarden staan in onze voorwaarden.

Enquiry

Overige gegevens die u al weet. Allemaal optioneel.

Wij leveren aan bedrijven in heel Europa en reageren binnen één werkdag.

MarketCodeSourcesSummary
Britain and Ireland2
Ireland (EN)IE2 sourcesThe HPRA detained 763,027 dosage units of falsified or unauthorised medicines in 2025. Ireland is Englis...
United Kingdom (EN)GB7 sourcesThe United Kingdom prohibits the sale or supply of any unauthorised medicinal product outright under the...
German-speaking markets3
Austria (EN)AT3 sourcesBASG has published a dedicated position holding that a research-use label does not change a peptide's cl...
Germany (EN)DE2 sourcesGermany applies the Arzneimittelgesetz alongside anti-doping legislation, and sets criminal thresholds f...
Switzerland (EN)CH5 sourcesSwissmedic regulates therapeutic products under the Heilmittelgesetz and runs a named, active cross-agen...
Benelux2
Belgium (EN)BE3 sourcesBelgium applies EU medicines law through the FAGG, which has published a GLP-1 warning. No dedicated pos...
Netherlands (EN)NL3 sourcesThe IGJ and the NVWA assess offerings jointly and have stated their position on research-use framing dir...
Nordics5
Denmark (EN)DK5 sourcesLaegemiddelstyrelsen maintains standing warnings, including on Melanotan. Research-chemical framing is a...
Finland (EN)FI2 sourcesFimea has warned against injectable peptides sold through social media. Semaglutide is a prescription me...
Iceland (EN)IS6 sourcesIceland applies the Medicinal Products Act No. 100/2020, administered by the Icelandic Medicines Agency....
Norway (EN)NO8 sourcesNorway applies the legemiddelloven and criminalises trade in listed doping substances under the general ...
Sweden (EN)SE5 sourcesLakemedelsverket has a published position on Melanotan II, and a government-commissioned report quantifi...
Baltics3
Estonia (EN)EE2 sourcesRavimiamet published a dated statement in June 2026 addressing internet-sold peptides marketed for resea...
Latvia (EN)LV4 sourcesThe ZVA regulates under the Farmacijas likums and has published dated GLP-1 safety communications. No pe...
Lithuania (EN)LT4 sourcesThe VVKT regulates under the Farmacijos istatymas and requires a wholesale distribution licence. No posi...
Central and Eastern Europe6
Croatia (EN)HR1 sourcesHALMED has published a general rule on online medicine sales. No notice naming research-labelled peptide...
Czechia (EN)CZ2 sourcesSUKL holds that most synthetic peptides meet the functional definition of a medicinal product, so classi...
Hungary (EN)HU5 sourcesOGYEI regulates medicines under Act XCV of 2005. A case-by-case research permit exists for controlled su...
Poland (EN)PL2 sourcesGIF and GIS have issued a joint public warning on synthetic peptides offered as chemical reagents. The P...
Slovakia (EN)SK3 sourcesSUKL named BPC-157, ipamorelin and melanotan directly in a July 2025 press release tied to an INTERPOL o...
Slovenia (EN)SI2 sourcesJAZMP published a dated warning on injectable peptides in April 2026 and names semaglutide and somatropi...
Southern Europe4
France (EN)FR3 sourcesANSM names compounds individually in its public alerts and has issued sanitary-police decisions against ...
Italy (EN)IT1 sourcesAIFA regulates under the Codice del farmaco and has warned on illegal GLP-1 supply through unauthorised ...
Portugal (EN)PT5 sourcesINFARMED governs medicines under the Estatuto do Medicamento and has flagged a rise in illegal online su...
Spain (EN)ES2 sourcesAEMPS has issued a formal notice on illegal GLP-1 supply and directs buyers to verify pharmacies through...
Eastern Mediterranean2
Greece (EN)GR4 sourcesEOF issued a public warning in July 2026, and related reporting names specific compounds. Regulatory att...
Turkey (EN)TR6 sourcesTurkey applies Law No. 1262 on Pharmaceutical and Medicinal Preparations of 1928 together with the regul...
Western Balkans4
Albania (EN)AL7 sourcesAlbania applies Law no. 105/2014 on medicinal products and the pharmaceutical service, as amended, admin...
Bosnia and Herzegovina (EN)BA5 sourcesBosnia and Herzegovina applies a single state-level act, the Law on Medicinal Products and Medical Devic...
North Macedonia (EN)MK7 sourcesNorth Macedonia applies the Law on Medicines and Medical Devices, published in the official gazette in 2...
Serbia (EN)RS5 sourcesSerbia applies the Law on Medicines and Medical Devices, published in the official gazette in 2010 and a...
Eastern Europe2
Moldova (EN)MD6 sourcesMoldova replaced its medicines statute in 2025: Law No. 153 of 19 June 2025 was published in the officia...
Ukraine (EN)UA6 sourcesUkraine regulates medicines under the Law on Medicinal Products of 4 April 1996, enforced by the State S...
South-eastern EU2
Bulgaria (EN)BG5 sourcesThe BDA regulates under the national medicines law and participates in the EU counterfeit-GLP-1 warning ...
Romania (EN)RO3 sourcesANMDMR operates under the EU medicines framework and has publicly identified a fraudulent tirzepatide pr...